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Abstract
Background: The molecular characteristics associated with the response to treatment in glioblastomas (GBMs)
remain largely unknown. We performed a retrospective study to assess the genomic characteristics associated with
the response of GBMs to either first-line chemotherapy or radiation therapy. The gene expression (n = 56) and
genomic profiles (n = 67) of responders and non-responders to first-line chemotherapy or radiation therapy alone
were compared on Affymetrix Plus 2 gene expression arrays and BAC CGH arrays.
Results: According to Verhaak et al.’s classification system, mesenchymal GBMs were more likely to respond to
radiotherapy than to first-line chemotherapy, whereas classical GBMs were more likely to respond to first-line
chemotherapy than to radiotherapy. In patients treated with radiation therapy alone, the response was associated
with differential expression of microenvironment-associated genes; the expression of hypoxia-related genes was
associated with short-term progression-free survival (< 5 months), whereas the expression of immune genes was
associated with prolonged progression-free survival (> 10 months). Consistently, infiltration of the tumor by both
CD3 and CD68 cells was significantly more frequent in responders to radiotherapy than in non-responders. In
patients treated with first-line chemotherapy, the expression of stem-cell genes was associated with resistance to
chemotherapy, and there was a significant association between response to treatment and p16 locus deletions.
Consistently, in an independent data set of patients treated with either radiotherapy alone or with both
radiotherapy and adjuvant chemotherapy, we found that patients with the p16 deletion benefited from adjuvant
chemotherapy regardless of their MGMT promoter methylation status, whereas in patients without the p16
deletion, this benefit was only observed in patients with a methylated MGMT promoter.
Conclusion: Differential expression of microenvironment genes and p16 locus deletion are associated with
responses to radiation therapy and to first-line chemotherapy, respectively, in GBM. Recently identified
transcriptomic subgroups of GBMs seem to respond differently to radiotherapy and to first-line chemotherapy.
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Background
Microarrays are an effective tool for the study of glioma
oncogenesis, and this technique has enabled the discov-
ery of new molecular pathways implicated in gliomagen-
esis [1,2]. Several studies have also described molecular
signatures related to histological type and to survival in
high-grade gliomas [3-10]. However, until now, few stu-
dies have used microarray technology to elucidate the
mechanisms associated with the response of the tumor
to treatment [11,12]. Despite an overall grim prognosis,
some patients with glioblastoma (GBM) do respond to
radiotherapy and chemotherapy and achieve prolonged
survival. The molecular characteristics associated with
prolonged progression-free survival (PFS) after radio-
therapy in GBM patients remain largely unknown. Stu-
dies demonstrate that patients with methylation of the
O6-methylguanine methyltransferase promoter
(MGMTP) benefit from radiotherapy with concomitant
temozolomide and from adjuvant chemotherapy with
alkylating agents [13,14]. However, it is likely that this it
is not the only mechanism underlying the chemosensi-
tivity of the tumor in these patients. In this study, we
examined the molecular characteristics associated with a
response to radiotherapy or to first-line chemotherapy
in GBMs in a cohort of patients treated with radiation
therapy alone or with first-line chemotherapy; the geno-
mic and transcriptomic profiles of responders and non-
responders were compared for both treatment groups.
Methods
Patients
All patients included in this study had de novo GBM
according to the 2007 World Health Organization Clas-
sification. A central pathological review was performed
by DFB. In order to focus more specifically on treatment
response, progression-free survival (PFS) and MacDo-
nald’s criteria of response were used as outcome mea-
sures rather than overall survival (OS), which may be
influenced by the use of salvage treatment at relapse.
Response to radiation therapy was defined in terms of
PFS. Patients were considered as responders to radio-
therapy if the PFS was >10 months and as non-respon-
ders if the PFS was <5 months. Patients treated with
radiotherapy and concomitant temozolomide were
excluded. In patients treated with first-line chemother-
apy, response was evaluated before radiotherapy accord-
ing to MacDonald’s criteria, and all of these patients
had an evaluable tumor [15]. These patients were trea-
ted with alkylating agents (BCNU or temozolomide).
Radiotherapy was administered at progression or after
six months of chemotherapy. Patients were considered
as responders if they achieved either partial or complete
response and as non-responders if they progressed
during chemotherapy. Patients’ clinical characteristics
are available in Additional file 1 Table S1.
Samples
Samples were provided as snap-frozen sections of areas
immediately adjacent to the region used for the histo-
pathological diagnosis. Only samples representative of
the tumor and from which high-quality DNA and/or
RNA could be obtained were selected (n = 86). For the
comparative genomic hybridization (CGH) array study,
67 samples were available: 21 responders to radiother-
apy, 18 non-responders to radiotherapy, 11 responders
to first-line chemotherapy and 17 non-responders to
first-line chemotherapy. The gene expression array study
was performed on 56 samples (including 37 samples
common to the CGH study): 19 responders to radio-
therapy, 15 non-responders to radiotherapy, 12 respon-
ders to first-line chemotherapy and 10 non-responders
to first-line chemotherapy.
DNA extraction and hybridization
DNA was extracted from frozen tumors using a standard
phenol-chloroform procedure
After digestion with DpnII (Ozyme, Saint Quentin en
Yvelines, France) and column purification (Qiaquick
PCR purification kit; Qiagen, Courtaboeuf, France),
tumor DNA was labeled with cyanine-5 (Perkin-Elmer,
Wellesley, MA) using the random priming method (Bio-
prime DNA labeling system; Invitrogen, Cergy-Pontoise,
France). Using the same procedure, we labeled control
DNA with cyanine-3. After ethanol co-precipitation with
210 g of human Cot-1 DNA (Invitrogen, Cergy-Pon-
toise, France), resuspension in hybridization buffer (50%
formamide), denaturation at 95°C for 10 minutes and
prehybridization at 37°C for 90 minutes, probes were
cohybridized on an aCGH slide. The aCGH slide was
previously preblocked with a buffer containing 2.6 mg
succinic anhydride, 118 ml N-methyl-2-pyrrolidinone
and 32 ml sodium tetraborate decahydrate, pH 8.0
(Sigma-Aldrich, Lyon, France). After washing, arrays
were scanned using an Agilent 2565BA scanner. Image
analysis was performed with SPOT v.2.1cc software, and
the ratios of Cy5/Cy3 signals were determined. The
human genome-wide CIT-CGHarray (V6), which con-
tains 4,434 sequence-verified bacterial artificial chromo-
some (BAC) and P1-derived artificial chromosome
clones, was chosen to obtain systematic coverage of the
genome and detailed coverage of regions containing
genes previously implicated in carcinogenesis. This array
was designed by the CIT-CGH consortium (Olivier
Delattre laboratory, Curie Institute, Paris; Charles Theil-
let laboratory, CRLC Val d’Aurelle, Montpellier; Stani-
slas du Manoir laboratory, IGBMC, Strasbourg) and
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IntegraGen. All clones were spotted in quadruplicate
(and spaced at approximately 670 kb intervals) on Ultra
Gaps slides (Corning Inc., Corning, NY).
RNA extraction and hybridization
Approximately 50 mg of tissue from each tumor was
used for total RNA extraction using the RNeasy Lipid
Tissue mini kit (Qiagen, CA) according to the manufac-
turer’s instructions. RNA quality was verified with the
Bioanalyzer System (Agilent Technologies, Palo Alto,
CA) using the RNA Nano Chip. RNA (1.5 μg) was pro-
cessed and hybridized to the Genechip Human Genome
U133 Plus 2.0 Expression array (Affymetrix, CA), which
contains over 54,000 probe sets analyzing the expression
levels of over 47,000 transcripts and variants. This
roughly corresponds to 29,500 distinct Unigene identi-
fiers. The processing was done according to the recom-
mendations of the manufacturer.
Immunohistochemistry
Immunohistochemistry was performed on tissue micro-
arrays (TMA) comprising 25 GBMs (15 responders and
10 non-responders to radiotherapy for whom enough
material was available) that were constructed from rou-
tinely processed formalin-fixed paraffin-embedded
tumor material. Areas of viable and representative
tumor, as determined by a review of all blocks, were
marked by a pathologist (DFB) prior to inclusion in the
TMA (3 × 0.6-mm cores for each tumor).
After steam-heat-induced antigen retrieval, 5-μm sec-
tions of formalin-fixed paraffin-embedded samples were
tested for the presence of CD3, CD20 and CD68 using a
polyclonal rabbit antibody (1:2) (Dako, Trappes, France),
a monoclonal mouse antibody (1:600, L26) (Dako) and a
monoclonal mouse antibody (1:5000, KP1) (Dako),
respectively. A Benchmark Ventana autostainer (Ven-
tana Medical Systems SA, Illkirch, France) was used for
detection, and TMA slides were simultaneously immu-
nostained to avoid inter-manipulation variability. Immu-
nostaining was scored by a pathologist (DFB) as follows:
0 = no positive cell; + = some positive cells; ++ = a
clear CD3, CD20 or CD68 infiltration.
MGMT promoter methylation status
The MGMT promoter’s (MGMTP) methylation status
was assessed in patients treated with first-line che-
motherapy. The DNA methylation status of the MGMT
promoter was determined by bisulfite modification and
subsequent Nested Methylation Specific PCR as pre-
viously described [16]. Sodium bisulfite specifically
modifies non-methylated cytosines, but not methylated
cytosines, to uracil. The sodium bisulfite treatment was
carried out using the EZ DNA Methylation Kit (Zymo
Research). The stage-1 PCR amplifies a 289-bp fragment
of the MGMT gene using primers that do not discrimi-
nate between methylated and unmethylated alleles. The
primer sequences are as follows: Forward 5′ GGA-
TATGTTGGGATAGTT 3′, Reverse 5′ CCAAAAACCC-
CAAACCC 3′. PCR conditions were as follows: 95°C for
15 min, then 30 cycles of 95°C for 30 s, 52°C for 30 s
and 72°C for 30 s, and finally 10 min at 72°C. The
stage-1 PCR products were then diluted 100-fold, and 5
μl was subjected to a stage-2 PCR in which primers
were specific to methylated or unmethylated alleles. Pri-
mer sequences are as follows: for the methylated reac-
tions, Forward 5′ TTTCGACGTTCGTAGGTTTTCG 3′,
Reverse 5′ GCACTCTTCCGAAAACGAAACG 3′; for
the unmethylated reactions, Forward 5′ TTTGT
GTTTTGATGTTTGTAGGTTTTTGT 3′, Reverse 5′
AACTCCACACTCTTCCAAAAACAAAACA 3′. PCR
conditions were as follows: 95°C for 15 min, then 30
cycles of 95°C for 30 s, 62°C for 30 s and 72°C for 30 s,
and finally 10 min at 72°C. PCR products were sepa-
rated on 2% agarose gels stained with ethidium bromide
and visualized under UV illumination. As a positive con-
trol for methylated alleles, we used DNA from lympho-
cytes treated with SssI methyltransferase (New England
Biolabs: Ozyme, St-Quentin-Yvelines, France) and modi-
fied by bisulfite treatment.
Data analysis summary
All raw and normalized data files for the microarray
analysis have been deposited under accessions E-TABM-
897 and E-TABM-898 at the European Bioinformatics
Institute http://www.ebi.ac.uk/microarray-as/ae. All
genomic and transcriptomic analysis was carried out
using R software http://www.R-project.org. For details,
please refer to Additional file 2.
Gene expression analysis
Raw gene expression data were normalized in batches
using the RMA method [17], yielding normalized log2
intensities, and quality control (QC) reports were gener-
ated using the affyQCReport R package. Clustering ana-
lysis was performed as previously reported [18]. To
identify differentially expressed genes, we used the Bayes
moderate T-test implemented in the limma R package.
Gene sets analysis using KEGG and Biocarta pathways
as well as Gene Ontology terms, Molecular Signature
Database gene sets and Stanford Microarray Database
gene sets was performed on the 1000 genes most differ-
entially expressed (500 genes up-regulated in responders
and 500 genes up-regulated in non-responders) using
hypergeometric tests. Custom gene sets were also built
using Murat et al.’s data and included in the gene sets
analysis [12]. In order to classify our samples according
to Phillips et al.’s system, we used their expression data
to build a centroid-based classifier, and after checking
that it was able to reclassify Phillips et al.’s samples
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properly, we classified our series based on these cen-
troids. In order to classify our samples according to Ver-
haak et al.’s system, we used their published centroid-
based classifier [8,10].
CGHarray analysis
For CGHarray data, after a QC and filtering step,
remaining spots were normalized using the lowess
print-tip method, then replicated spots were averaged,
yielding normalized log2 ratios. Smoothed log2 ratios
were then obtained using the tilingArray R package.
Gain and loss status, respectively, were determined for
each clone based on a smoothed log2 ratio above
(below) the distribution mode plus (minus) one standard
deviation. Homozygous deletions and amplicons, respec-
tively, were detected using a sample-based estimate of
the tumor cell rate RTC as clones yielding smoothed
log2 ratios below log2(1-RTC) (above log2(1+ 1.5* RTC)).
Recurrent minimal genomic alterations (MCR) were
obtained as previously described [19]. To identify clones
or regions with differential genomic status, we used
Fisher’s exact test.
In all cases, control for multiple testing was done with
the Benjamini and Hochberg approach.
Survival curves were calculated according to the
Kaplan-Meier method, and differences between curves
were assessed using the log-rank test.
Independent data set
The influence of the p16 homozygous genomic deletions
was studied in an independent data set of 222 GBMs
from the Pitié-Salpêtrière Hospital’s neuro-oncology
department; the p16 deletion and MGMTP methylation
statuses of these data set samples were available. This
data set consists largely of patients whose data have
been previously published [20]. These patients were
treated with either radiation therapy alone or with radia-
tion therapy followed by adjuvant chemotherapy with
alkylating agents (BCNU or temozolomide).
Results
Classical and mesenchymal GBMs respond differently to
radiotherapy and to first-line chemotherapy
First, in order to assess if responders and non-respon-
ders to either radiation therapy or first-line chemother-
apy corresponded to different transcriptomic subgroups
of GBMs, we performed an unsupervised hierarchical
clustering analysis of the 56 GBMs. As shown in Figure
1, three main transcriptomic subgroups were identified.
This clustering was robust and conserved across differ-
ent gene lists and clustering methods. The centroids
generating this classification are provided in Additional
file 1 Table S2. However, none of the three clusters was
enriched in responders or non-responders, and neither
the PFS nor the OS differed between the three clusters.
As shown in Figure 1, some responders and non-
responders had very similar gene expression profiles.
Next, in order to assess if transcriptomic subgroups of
GBMs previously identified in larger series of patients
were associated with a specific pattern of response to
radiotherapy or to chemotherapy, we classified our 56
samples according to Phillips et al.’s and Verhaak et al.’s
transcriptomic classifications and estimated the response
rate in each subgroup [8,10]. As shown in Figure 1,
there was a significant but not complete overlap
between our three subgroups of GBMs and the classes
of GBMs identified in these studies. As shown in Table
1, Verhaak et al.’s classes (but not Phillips et al.’s
classes) were significantly associated with response to
treatment. Indeed, we found that GBMs classified as
mesenchymal were more likely to respond to radiother-
apy (8 out of 10) than to chemotherapy (1 out of 7)
(Fisher’s exact test, p = 0.01), whereas GBMs classified
as classical were more likely to respond to chemother-
apy (7 out of 8) than to radiotherapy (3 out of 11) (Fish-
er’s exact test, p = 0.02). Accordingly, as shown in
Figure 2, patients with a mesenchymal GBM had a bet-
ter outcome when treated with radiotherapy, whereas
patients with a classical GBM had a better outcome
when treated with first-line chemotherapy. In the neural
GBMs, the overall response rate to either radiotherapy
or chemotherapy was higher than in the other sub-
groups (8 responders out of 9 neural GBMs versus 23
responders out of 47 non-neural GBMs, Fisher’s exact
test, p = 0.03).
Molecular characteristics associated with response to
radiation therapy
In a second step, we focused on all patients treated with
radiotherapy alone to identify the molecular characteris-
tics associated with a response to radiation therapy.
Comparison of the genomic profiles of responders (n =
21) and non-responders (n = 18) demonstrated that the
two groups of patients had very similar genomic profiles
(Figure 3). In both groups, there was a high frequency
of chromosome 7 gain and chromosome 10 loss, consis-
tent with the most frequently observed genomic
abnormalities in GBMs. Only three Minimal Common
Regions (MCR) were significantly different between the
two groups (Fisher’s exact test p-value <0.05), albeit at a
low frequency (Table 2). Several genes located in these
MCRs were also differentially expressed, but to our
knowledge, none of them has been reported to play a
role in response to radiation therapy (Table 2 and Addi-
tional file 1 Table S3).
Therefore, we focused on the comparison of the gene
expression profiles of responders (n = 19) and non-
responders (n = 15). As suggested by the observation
that responders and non-responders to radiotherapy
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could have very similar expression profiles, the differ-
ences between responders and non-responders were
modest; nevertheless, 417 genes were up-regulated in
non-responders and 449 up-regulated in responders
with p < 0.05 and fold change > 1.5 (Additional file 1
Table S4). To characterize the differences between the
two groups, we performed a gene set analysis on the
1000 genes most differentially expressed (500 genes up-
regulated in responders and 500 genes up-regulated in
non-responders). This demonstrated that these gene
Figure 1 Unsupervised clustering of the 56 glioblastomas. Unsupervised hierarchical clustering of the 56 GBMs. The heatmap was done with
the 72 probe sets used in the centroid classifier that was able to generate the 3 groups identified through unsupervised clustering (Additional
file 1 Table S2). Samples and genes were clustered using Ward’s linkage and 1-Pearson correlation coefficient. For each probe set, the lowest and
highest intensity values are displayed in blue and red, respectively. Treatment: C = First-line chemotherapy, R = Radiotherapy. Response: N =
non-responder, Y = responder. Phillips = class according to Phillips et al.’s classification [8], blue P = Proneural, green P = Proliferative, M =
Mesenchymal. Verhaak = class according to Verhaak et al.’s classification [10], N = Neural, C = Classical, M = Mesenchymal, P = Proneural. The
GBMs were classified into three groups: one group enriched in EGFR-amplified patients (n = 19, blue cluster), one group characterized by a high
level of expression of immune and extra-cellular matrix genes (n = 12, red cluster) and one group characterized by a higher of expression of
neural genes (n = 25, green cluster). There was a significant overlap when using Phillips et al.’s classes (Fisher’s exact test p-value = 1.7 × 10-8)
and a larger overlap with Verhaak et al.’s classes (Fisher’s exact test p-value = 2.2 × 10-14).
Table 1 Response to radiotherapy according to Phillips and Verhaak classifications
Response to chemotherapy Response to radiotherapy Fisher’s
exact test
No Yes No Yes
Phillips subgroups
Mes. 4 7 5 6 NS
PN 2 3 6 7 NS
Proliferative 4 2 4 6 NS
Verhaak subgroups
Mes. 6 1 2 8 p = 0.01*
Neural 0 3 1 5 p = 0.03°
PN 3 1 4 3 NS
Classical 1 7 8 3 P = 0.02*
Mes. = Mesenchymal, PN = Proneural
* comparison of the frequencies of response to chemotherapy and to radiotherapy in mesenchymal and classical GBMs
° comparison of the frequency of response to treatment in neural vs. other classes of GBMs
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lists were enriched in genes with very different ontolo-
gies (Table 3, Table 4 and Additional file 1 Table S5).
The list of up-regulated genes in responders was most
significantly enriched in genes involved in the immune
response, namely in immune genes previously reported
to be associated with an improved outcome after radio-
chemotherapy (Cluster G24, Table 4) [12]. This enrich-
ment was seen in non-specific inflammatory response
genes as well as in genes involved in the B cell-mediated
response and T cell activation (Table 3, Table 4). In
order to validate these findings at the protein level, an
immunohistochemical study of CD3, CD20 and CD68
markers was performed in the tumors of responders and
non-responders to radiotherapy. Neither GBM samples
of responders nor those of non-responders were infil-
trated by CD20 cells. However, infiltration by CD3 cells
and by both CD3 and CD68 was much more frequent
in responders than in non-responders to radiotherapy
(Table 5, Fisher’s exact test, p-value = 0.04). On the
other hand, the list of up-regulated genes in non-
responders was most significantly enriched in genes
induced by hypoxia, suggesting a higher level of hypoxia
in the non-responders (Table 3, Table 4). As hypoxia is
a well-known mechanism of radiation resistance, these
results suggest that even in GBMs, which are highly
hypoxic tumors, a higher level of hypoxia raises the level
of resistance to radiation therapy.
Molecular characteristics associated with response to
first-line chemotherapy
Comparison of the genomic profiles (gains, losses,
homozygous deletions and amplifications) of responders
(n = 11) versus non-responders (n = 17) to first-line
chemotherapy (in contrast to radiation therapy) demon-
strated substantial genomic differences (Figure 4).
CDKN2A (p16) locus homozygous deletions on 9p21,
EGFR amplification and 24 MCRs (3 loss and 21 gains)
were significantly associated with response to che-
motherapy (Fisher’s exact test, p < 0.05) (Table 2 and
Additional file 1 Table S6). CDKN2A (p16) locus homo-
zygous deletion was the most significant event; it was
observed in 82% of responders but in none of the non-
responders (Fisher’s exact test, p < 10-4). It was asso-
ciated with a significant down-regulation of the
Figure 2 Survival according to treatment in mesenchymal and classical GBMs. Progression-free survival and overall survival according to
treatment (radiotherapy = red, first-line chemotherapy = black) in the GBMs of the present study classified as mesenchymal or classical
according to Verhaak et al.’s classes [10].
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expression of CDKN2A in responders (p = 0.04). Con-
cerning MTAP and CDKN2B, which are also located in
the p16 locus, a significant down-regulation of the
expression in responders was observed only for MTAP
(p = 0.0003). Among the other genomic alterations that
have been reported to alter the retinoblastoma (RB) sig-
naling pathway in GBMs (i.e., CDK4 or CDK6 or
CCND2 amplification and RB1 or CDKN2C homozygous
deletion), we found a CDK4 amplification in three non-
responders and a CCND2 amplification in one respon-
der who had also a p16 deletion. Thus, in contrast to
p16 deletion, other genomic alterations disrupting the
RB pathway did not seem to be associated with response
to chemotherapy.
EGFR amplification was more frequently observed in
responders than in non-responders (81% vs. 35%, Fish-
er’s exact test, p = 0.02). All lost MCRs were located on
chromosome 9p22-24, and these loci were not indepen-
dent. Among the genes located in these MCRs (Table
2), none has been reported to be involved in chemosen-
sitivity. Gained MCRs were located on chromosomes
11p, 11q, 17p, 19p, 19q, 20p and 20q. Genes located in
these MCRs and significantly overexpressed in respon-
ders are summarized in Table 2. To our knowledge,
none of these genes has been associated with
chemosensitivity.
Surprisingly, MGMTP methylation analysis demon-
strated that most patients in this series were MGMTP
unmethylated (8 out of 11 responders and 14 out of 17
non-responders); thus, these genomic abnormalities may
actually represent alternative mechanisms of chemosen-
sitivity in MGMTP unmethylated patients.
Next, we compared the gene expression profiles of
responders (n = 12) and non-responders (n = 10). The
differences between the two groups were less important
than the analogous differences between responders and
non-responders to radiotherapy, with 292 genes being
up-regulated in non-responders and 203 genes being
up-regulated in responders with a p-value <0.05 and a
fold change >1.5 (Additional file 1 Table S7). Gene set
analysis on the 1000 genes most differentially expressed
between the two groups (500 genes up-regulated in
responders and 500 genes up-regulated in non-respon-
ders) was performed. In agreement with the genomic
analysis, the list of up-regulated genes in non-respon-
ders was enriched in genes located on 9p (Table 6).
Interestingly, this gene list was also enriched in genes
reported to be up-regulated in embryonic and neural
stem cells, whereas the list of genes up-regulated in
responders was enriched in genes up-regulated in the
normal brain, suggesting a link between resistance to
chemotherapy and a more undifferentiated phenotype of
Figure 3 Genomic profiles of patients with short and long PFS after radiation therapy. CGH array genomic profiles of the patients with
short (< 5 months) and long (> 10 months) PFS after radiotherapy. For each chromosome, the telomere of the short arm is on the left and the
telomere of the long arm is on the right. Genomic gains and losses are shown in red and green, respectively. The y-axis corresponds to the
frequency of gains and losses in each group of patients.
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Table 2 Minimal Common Regions differentiating responders from non-responders to radiation therapy and first-line
chemotherapy
Event Chr Treatment Differentially expressed genes located in the MCR
Radiation therapy
% in
NR
% in
R
p-
value
Loss 5p15.3 0 33 0.04
Loss 5p15.2-3 0 29 0.01 CMBL (FC = 1.3)
Gain 17q24-25 22 0 0.02 TANC2 (FC = 1.1), DCAF7 (FC = 1.2), LRRC37A (FC = 1.3), PITPNC1 (FC = 1.6)
Chemotherapy
% in
NR
% in
R
p-
value
Amp. 7p11.2 0.35 0.81 0.02
Del. 9p21.3 0 0.82 < 10-4 MTAP (FC = 2), CDKN2A (FC = 2.6)
Loss 9p24 0.12 0.64 0.01
Loss 9p24 0.12 0.64 0.01 KIAA1432 (FC = 1.4), KDM4C (FC = 1.2)
Loss 9p24;p23;p22 0.12 0.64 0.01 ZDHHC21 (FC = 1.6)
Gain 11p15 0.18 0.64 0.02 PGAP2 (FC = 0.8)
Gain 11q13 0.18 0.91 0.0003 C11orf68 (FC = 0.8), B3GNT1 (FC = 0.75), RAB1B (FC = 0.86)
Gain 17p13 0.18 0.64 0.02 CRK (FC = 0.83), INPP5K (FC = 0.88), TSR1 (FC = 0.87), METT10 D (FC = 0.77), SGSM2(FC = 0.75)
Gain 17p13 0.18 0.64 0.02 METT10 D (FC = 0.77)
Gain 19p13.3 0.35 0.91 0.006 PPAP2C (FC = 0.74), SHC2 (FC = 0.8), MOBKL2A (FC = 0.81), SCAMP4 (FC = 0.8), BTBD2 (FC = 0.8),
FAM108A1 (0.86), SF3A2 (FC = 0.74), AP3D1 (0.77), GNG7 (0.46), ZNF555 (0.82), DOHH (0.82), C19orf29
(0.8), NFIC (0.75)
Gain 19p13.3;
p13.2;p13.1
0.29 0.91 0.002 SLC25A23 (0.6), CLEC4 M (0.85), ZNF846 (0.7), OLFM2 (0.6), S1PR2 (0.8), DHPS (0.85), TNPO2 (0.76),
ZNF791 (0.77)
Gain 19p13.1 0.29 0.91 0.002 EPS15L1 (0.83), OCEL1 (0.85), TMEM161A (0.82), NCAN (0.3)
Gain 19p12 0.29 0.91 0.002
Gain 19p12;p11 0.29 0.91 0.002
Gain 19q11;q12 0.29 0.82 0.002 FXYD3 (0.84)
Gain 19q12;
q13.1
0.35 0.91 0.006 FAM98C (0.77)
Gain 20p13 0.12 0.82 0.0004 ZCCHC3 (0.81), SOX12 (0.84), RBCK1 (0.8), CSNK2A1 (0.81), MAVS (0.8), ATRN (0.76)
Gain 20p12.3;
p11.2
0.18 0.64 0.002 RRBP1 (0.73)
Gain 20p11.2 0.12 0.64 0.003
Gain 20p11.2;
p11.1;
q11.1;q11.2
0.24 0.73 0.02 CST8 (0.87)
Gain 20q11.2 0.24 0.82 0.006 PLUNC (0.88), CHMP4B (0.83)
Gain 20q11.2 0.24 0.82 0.006 CHMP4B (0.83), LOC647979 (0.67)
Gain 20q11.2;q12 0.18 0.73 0.006 SNHG11 (0.75)
Gain 20q13.1 0.18 0.73 0.006 SLC13A3 (0.81)
Gain 20q13.1 0.24 0.73 0.02 PREX1 (0.72)
Gain 20q13.3 0.24 0.73 0.02 CDH4 (0.5), OSBPL2 (0.82)
Chr= chromosome, NR= Non-responder, R= Responder, % = Frequency of the event, FC= Fold change in NR versus R, Amp. = Amplification, Del. = Homozygous
deletion
Recurrent alterations were defined for the entire population of samples if the identical alteration was present in at least two samples. Computation of recurrent
minimal genomic alterations was done in a similar way to a method previously described using original R code [19]. Comparison of the genomic profiles of
responders (n = 21) and non-responders (n = 18) demonstrated that three Minimal Common Regions (MCRs) were significantly different between the two groups
(Fisher’s exact test p-value <0.05). Comparison of the genomic profiles of responders (n = 11) versus non-responders (n = 17) to first-line chemotherapy
demonstrated substantial genomic differences, with twenty-four MCRs being significantly (p < 0.05) associated with the chemotherapy response. Differentially
expressed genes with a p-value <0.05 and located in the MCR are shown with their corresponding fold changes.
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the tumor (Table 6, Table 7 and Additional file 1 Table
S8). Consistently, the list of genes up-regulated in
responders was enriched in a set of normal brain genes
(Cluster 18, Table 7) associated with improved outcome
after chemoradioherapy whereas the list of genes up-
regulated in non-responders was enriched in a set of
stem-cell genes (Cluster 28_98, Table 7) associated with
a worse outcome after concomitant chemoradiotherapy
[12]. Among the stem-cell genes, HOXA10 and
HOXC6, were the most up-regulated genes in non-
responders to chemotherapy.
Impact of p16 locus homozygous deletions on outcome
after adjuvant chemotherapy in an independent data set
As the p16 locus homozygous deletion was the most
consistent finding in patients responding to first-line
chemotherapy, we focused on the study of this genomic
abnormality in an independent series of patients treated
either by radiotherapy alone (n = 79) or by radiotherapy
followed by adjuvant chemotherapy (n = 143) for whom
the MGMTP methylation status was also available
(Table 8). We hypothesized that, if this genomic
abnormality was consistently associated with chemosen-
sitivity, then, as has been demonstrated for MGMTP
methylation, the benefit of adjuvant chemotherapy
would be more pronounced in the group of patients
with the p16 deletion.
In the patients with the p16 deletion, we found that,
regardless of MGMTP methylation status, those treated
with radiotherapy and adjuvant chemotherapy had a sig-
nificantly longer PFS (10.7 vs. 7.9 months, p = 0.007, if
unmethylated; 9.7 vs. 7.9 months, p = 0.01, if methy-
lated) and OS (25.3 vs. 12.2 months, p = 0.002, if
unmethylated; 18.6 vs. 12.2 months, p = 0.01, if methy-
lated) than those treated with radiotherapy alone (Figure
5). This association was independent of age, Karnofsky
performance status and type of surgery. In contrast,
among patients without the p16 deletion who were trea-
ted with radiotherapy and adjuvant chemotherapy, only
those patients with a methylated MGMTP had a longer
PFS (11.8 vs. 6.3 months, p = 0.008) and a longer OS
(18.4 vs. 15 months, p = 0.05) than those treated with
radiotherapy alone (Figure 5). Patients without the p16
deletion treated with radiotherapy and adjuvant che-
motherapy and with an unmethylated MGMTP did not
fare better than patients without the p16 deletion who
were treated with radiotherapy alone.
The finding that MGMTP unmethylated patients benefit
from adjuvant chemotherapy when the p16 locus is
deleted is consistent with the association between p16
deletion and chemosensitivity. However, we found no
additive effect between MGMTP methylation and p16
deletion. Indeed, in the group of patients with a p16 dele-
tion who were treated with radiotherapy and adjuvant che-
motherapy, the outcomes were similar between MGMTP
methylated and unmethylated patients (Figure 5).
Discussion
Several microarray studies have focused on the relation-
ship between gene expression profiles, genomic profiles
and overall survival in high-grade gliomas [4,6-10,21],
but few studies have used microarray technology to
describe the molecular characteristics associated with
the response of the tumor to therapy [11,12]. A recent
study examined the gene expression profile and survival
in GBM patients treated with either radiation therapy
alone or with concomitant chemoradiotherapy with
temozolomide, but this study essentially focused on
patients treated with concomitant chemoradiotherapy
[12]. Thus, until now, no study had performed an exten-
sive microarray-based study of the gene expression and
genomic characteristics of GBMs with different
responses after either radiation therapy alone or first-
line chemotherapy. The present study has several limita-
tions. Beside the limited number of patients, the
response criteria used to define response to radiotherapy
are debatable. Furthermore, the fact that most respon-
ders to first-line chemotherapy were MGMTP
Table 3 Summary of the most relevant gene sets enriched in responders and non-responders to radiotherapy
Gene sets most significantly enriched in responders BH
adjusted
p-value
Gene sets most significantly enriched in non-
responders
BH adjusted
p-value
Murat et al. immune gene cluster (G24) < 10-4 MSigDB C2 pathways MENSE_HYPOXIA_UP < 10-4
GO:0042613 - MHC class II protein complex < 10-4 SMD processes core_hypoxia1_sw < 10-4
SMD cancerModules Immune (humoral) and inflammatory
response
< 10-4 MSigDB C2 pathways HYPOXIA_REVIEW 0.001
GO:0006955 - immune response < 10-4 SMD cancerModules DRG (dorsal root ganglia) genes 0.006
MSigDB C2 pathways LEE_TCELLS2_UP < 10-4 MSigDB C2 pathways HYPOXIA_REG_UP 0.01
GO:0006954 - inflammatory response < 10-4
GO:0045087 - innate immune response < 10-4
Summary of gene sets analysis using KEGG, Biocarta pathways, Gene Ontology (GO) terms, Molecular Signatures Database (MSigDB) gene sets, Stanford
microarray database (SMS) and Murat et al.’s gene sets [12]. BH: Benjamini and Hochberg.
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unmethylated suggests that this group of patients might
not be completely representative of the entire popula-
tion of GBMs. However, despite these limitations, the
present study provides new information regarding the
molecular characteristics associated with responses to
radiotherapy and to first-line chemotherapy in GBMs.
Our first objective was to assess if responders and
non-responders to radiotherapy or to chemotherapy cor-
responded to distinct transcriptomic subgroups of
GBMs. Using unsupervised hierarchical clustering, we
were unable to identify any transcriptomic subgroups of
responders or non-responders. However, we found an
Table 4 Most differentially expressed genes between responders and non-responders to radiotherapy
Twenty most up-regulated genes in responders to radiotherapy
Probe set Gene symbol Description FC p-value
211538_s_at HSPA2 Heat shock 70 kDa protein 2 3.4 < 10-4
209687_at CXCL12 Chemokine ligand 12 (SDF1) 2.6 0.001
209480_at HLA-DQB1 MHC complex, class II, DQ beta 1 2.5 0.023
221900_at COL8A2 Collagen, type VIII, alpha 2 2.5 0.004
226818_at MPEG1 Macrophage expressed gene 1 2.4 < 10-4
219759_at ERAP2 Endoplasmic reticulum aminopeptidase 2 2.3 0.019
220146_at TLR7 Toll-like receptor 7 2.3 0.002
222881_at HPSE Heparanase 2.2 < 10-4
239270_at PLCXD3 Phosphatidylinositol-specific Phospholipase C, × domain containing 3 2.2 0.001
218858_at DEPDC6 DEP domain containing 6 2.2 0.001
209343_at EFHD1 EF-hand domain family, D1 2.2 0.004
205034_at CCNE2 Cyclin E2 2.2 0.004
223170_at TMEM98 Transmembrane protein 98 2.2 0.012
203184_at FBN2 Fibrillin 2 2.2 0.020
1557395_at LOC255130 2.2 0.035
204466_s_at SNCA Synuclein, alpha 2.1 0.017
228598_at DPP10 Dipeptidyl-peptidase 10 2.1 0.023
1567628_at CD74 CD74 molecule, MHC complex 2.1 0.006
219750_at TMEM144 Transmembrane protein 144 2.1 0.04
228376_at GGTA1 Glycoprotein, alpha-galactosyltransferase 1 2.1 0.006
Twenty genes most differentially up-regulated in non-responders to radiotherapy
220405_at SNTG1 Syntrophin, gamma 1 3.4 0.001
236761_at LHFPL3 Lipoma HMGIC fusion partner-like 3 3.2 0.035
204913_s_at SOX11 SRY (sex determining region Y)-box 11 3.1 0.038
205230_at RPH3A Rabphilin 3A homolog (mouse) 2.8 0.014
202859_x_at IL8 Interleukin 8 2.8 0.023
206201_s_at MEOX2 Mesenchyme homeobox 2 2.7 0.047
230498_at MCHR1 Melanin-concentrating hormone receptor 1 2.7 0.006
1554452_at HIG2 Hypoxia-inducible protein 2 2.7 0.003
206984_s_at RIT2 Ras-like without CAAX 2 2.6 0.023
225285_at BCAT1 Branched chain aminotransferase 1, cytosolic 2.4 < 10-4
223278_at GJB2 Gap junction protein, beta 2, 26kDa 2.4 0.021
205358_at GRIA2 Glutamate receptor, ionotropic, AMPA 2 2.4 0.027
227361_at HS3ST3B1 Heparan sulfate (glucosamine) 3-O-sulfotransferase 3B1 2.4 0.038
211527_x_at VEGFA Vascular endothelial growth factor A 2.4 0.015
219196_at SCG3 Secretogranin III 2.3 0.025
232099_at PCDHB16 Protocadherin beta 16 2.3 0.010
217562_at FAM5C Family with sequence similarity 5, member C 2.3 0.023
214920_at THSD7A Thrombospondin, type I, domain containing 7A 2.3 0.025
202499_s_at SLC2A3 Solute carrier family 2 (facilitated glucose transporter), member 3 2.2 < 10-4
202912_at ADM Adrenomedullin 2.2 0.016
List of the 20 genes most up-regulated and with a p-value <0.05 in responders versus non-responders and in non-responders versus responders to radiotherapy.
FC: Fold change, p-value: Limma T-test p-value. Immune genes and hypoxia genes are underlined in responders and non-responders, respectively.
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association between Verhaak et al.’s transcriptomic clas-
sification of GBMs and the response rates to radiother-
apy and to chemotherapy [10]. This classification has
been established by the Cancer Genome Atlas Network
and is presently the most accomplished transcriptomic
classification system for GBMs [10]. It distinguishes four
subgroups of GBMs. Classical GBMs are characterized
by a 95% rate of EGFR amplification, p16 locus deletion
and an astrocytic gene expression profile. Mesenchymal
GBMs are characterized by a high rate of NF1 muta-
tion/deletion and an activated astroglial gene expression
profile. Proneural GBMs are characterized by a high rate
of PDGFRA amplification and IDH1 mutations and an
oligodendroglial gene expression profile. Neural GBMs
are characterized by a normal brain-like gene expression
profile [10]. Using this classification, it has been sug-
gested that classical and mesenchymal GBMs, unlike
proneural GBMs, benefit from more aggressive treat-
ment consisting of concomitant chemoradiotherapy or
radiotherapy followed by prolonged adjuvant che-
motherapy (> 3 cycles). However, there are currently no
data concerning the response rates of these subgroups
of GBMs to either radiotherapy alone or to first-line
chemotherapy. Interestingly, we found that classical
GBMs were more likely to respond to first-line che-
motherapy than to radiotherapy (87.5% vs. 27%, p =
0.02), whereas mesenchymal GBMs were more likely to
respond to radiotherapy than to first-line chemotherapy
(80% vs. 15%, p = 0.01). We also observed that neural
GBMs had higher response rates to both radiotherapy
and chemotherapy than the other subtypes (88% versus
49%, p = 0.03). Of course, these results must be consid-
ered with caution because of the limited number of
GBMs studied and because of the selection criteria used
in the present study. However, in line with Verhaak et
al.’s findings, these results suggest that these transcrip-
tomic subgroups of GBMs might benefit from different
therapeutic strategies.
In our cohort, the transcriptomic and genomic charac-
teristics associated with a therapeutic response differed
between patients treated with radiation therapy and
patients treated with first-line chemotherapy. These
Table 5 CD20, CD3 and CD68 immunohistochemistry in
responders and non-responders to radiation therapy
Responders Non-responders Fisher’s exact
test
Negative + +
+
Negative + +
+
p-value
CD20 15 0 0 10 0 0 NS
CD3 4 6 5 7 3 0 0.04
CD68 5 7 3 6 4 1 NS
CD3 and
CD68
5 10 8 2 0.04
Figure 4 Genomic profiles of non-responders and responders to first-line chemotherapy. CGH array genomic profiles of the non-
responders and the responders to first line chemotherapy. For each chromosome, the telomere of the short arm is on the left and the telomere
of the long arm is on the right. Genomic gains and losses are shown in red and green, respectively. p16 locus homozygous deletion is shown in
yellow. The y-axis corresponds to the frequency of gains and losses in each group of patients.
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results are in agreement with a recent study showing
that the molecular characteristics predictive of resistance
to chemoradiotherapy were not predictive of resistance
to radiation therapy alone [12]. They are also in agree-
ment with the finding that in the present study, respon-
ders to radiotherapy were mostly mesenchymal GBMs,
whereas responders to chemotherapy were mostly classi-
cal GBMs, though this might also be related to the dif-
ferent criteria used to define response in our two groups
of patients.
In examining the differences between responders and
non-responders to radiation therapy, our main finding is
relevant to the differential expression of genes impli-
cated in the micro-environment. As observed in another
study, genes implicated in the innate immune response
were enriched in responders to radiation therapy [12].
Consistently, we found that the tumors of responders
were much more frequently infiltrated by both T lym-
phocytes and microglial cells than were those of non-
responders. This finding is also in agreement with the
high response rate to radiotherapy observed among the
mesenchymal GBMs. Indeed, these GBMs are character-
ized by a high level of inflammation and microglial infil-
tration [10]. This finding suggests that stimulating
innate immunity might enhance tumor control and
encourage the use of immunotherapy [22]. It is also
interesting to link this result with epidemiological stu-
dies that have demonstrated a lower incidence of glio-
mas in patients with allergies, as these studies suggest
that particular immune characteristics may protect
against gliomas [23]. Recently, the expression of inflam-
mation genes in gliomas has also been inversely corre-
lated with the expression of CD133, a marker of stem
cells [24]. On the other hand, hypoxia-induced genes
were enriched in non-responders to radiation therapy.
Hypoxia is a well known factor involved in radiation
resistance [25]. GBMs are highly hypoxic tumors, and
hypoxia plays a key role in their pathogenesis [26]. It
enhances angiogenesis and selects for highly malignant
cells resistant to hypoxic cell death and with increased
migration capabilities [26]. Furthermore, hypoxia has
been shown to maintain tumor stem cells in GBMs,
which have been suggested to promote radioresistance
[27]. Hypoxia gene expression profiles have been shown
to be associated with poor outcome in several cancers,
but not in GBMs [28]. The volume of the hypoxic
tumor and the maximum level of hypoxia in GBMs
measured using [18F]fluoromisonidazole positron emis-
sion tomography have been associated with a shorter
PFS and OS after radiation therapy [29], and similar
results have been obtained using binding of EF5 to mea-
sure tissue hypoxia [30]. However, up to now, therapeu-
tic strategies aiming at reducing hypoxia to increase the
efficacy of radiation therapy have failed to demonstrate
efficacy in gliomas [31]. Interestingly, in our series,
VEGFA was one of the most overexpressed hypoxia-
induced genes in non-responders. VEGFA enhances
endothelial cell survival, proliferation, migration and
blood vessel permeability [32,33]. This in turn contri-
butes to heterogeneous oxygen delivery and hypoxia
[34]. Anti-VEGF treatments have been demonstrated to
normalize the structure and function of the abnormal
neovasculature [34-36], thus restoring normal blood
flow, diminishing vascular leakage, reducing hypoxia and
ultimately making tumor cells more sensitive to radia-
tion therapy. Therefore, the overexpression of VEGFA
and hypoxia-induced genes in non-responders to radia-
tion therapy in our cohort supports the use of therapies
that combine anti-angiogenics with radiation therapy to
enhance the efficacy of radiotherapy by reducing tumor
hypoxia [35].
In examining the differences between responders and
non-responders to first-line chemotherapy, we found
that the genes up-regulated in non-responders were
enriched in neural and embryonic stem-cell genes,
whereas those up-regulated in responders were enriched
in normal brain genes. This is consistent with the find-
ing in another study that a stem-cell gene expression
profile was associated with shorter survival after com-
bined radiochemotherapy [12] and with several reports
suggesting that cancer stem cells are more resistant to
chemotherapy [37-39].
Table 6 Summary of the most relevant gene sets enriched in responders and non-responders to chemotherapy
Gene sets most significantly enriched in
responders
BH
adjusted
p-value
Gene sets most significantly enriched in non-
responders
BH adjusted p-
value
MSigDB C2 pathways AGEING_BRAIN_UP < 10-4 SMD chromArms 9p 0.005
SMD cancerModules CNS genes < 10-4 MSigDB C2 pathways STEMCELL_NEURAL_UP 0.007
Murat et al. normal brain gene cluster (G18) < 10-4 MSigDB C2 pathways LEE_TCELLS2_UP 0.01
SMD tissues Brain_sw 0.06 GO:0001952 - regulation of cell-matrix adhesion 0.02
MSigDB C2 pathways STEMCELL_EMBRYONIC_UP
Murat et al. stem cell gene cluster (G28_G98)
0.02
1
Summary of gene sets analysis using KEGG, Biocarta pathways, Gene Ontology (GO) terms, Molecular Signatures Database (MSigDB) gene sets and Stanford
microarray database (SMD) and Murat et al.’s gene sets [12]. BH: Benjamini and Hochberg.
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Another interesting result of our study is that the
most striking genomic difference between responders
and non-responders to first-line chemotherapy was the
overrepresentation of homozygous p16 locus deletions
in responders. P16/CDKN2A deletions occur in about
30-50% of GBMs but in 95% of classical GBMs [10,40].
Consistently, we found that classical GBMs were more
likely to respond to first-line chemotherapy. The asso-
ciation between p16 deletions and enhanced chemo-
sensitivity to adjuvant temozolomide has already been
Table 7 Most differentially expressed genes between responders and non-responders to first-line chemotherapy
Twenty genes most up-regulated in responders to chemotherapy
Probe set Gene symbol Description FC p-value
203296_s_at ATP1A2 ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide 5.4 0.003
230865_at LIX1 Lix1 homolog (mouse) 3.8 0.005
209728_at HLA-DRB4 MHC, DR beta 4 3.8 0.002
223075_s_at AIF1L Allograft inflammatory factor 1-like 3.6 0.002
210738_s_at SLC4A4 Solute carrier family 4, sodium bicarbonate cotransporter, member 4 3.5 0.02
223434_at GBP3 Guanylate binding protein 3 3.5 0.01
228581_at KCNJ10 Potassium inwardly-rectifying channel, subfamily J, member 10 3.4 0.008
229778_at C12orf39 chromosome 12 open reading frame 39 3.3 0.02
205143_at NCAN Neurocan 3.3 0.02
225911_at NPNT Nephronectin 3.3 0.004
209074_s_at FAM107A Family with sequence similarity 107, member A 3.3 0.004
206306_at RYR3 Ryanodine receptor 3 3.1 0.04
217057_s_at GNAS GNAS complex locus 3.1 0.03
220029_at ELOVL2 Elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 2 3.1 0.008
1558010_s_at SLC1A2 Solute carrier family 1 (glial high affinity glutamate transporter), member 2 3.1 0.01
223699_at CNDP1 Carnosine dipeptidase 1 (metallopeptidase M20 family) 2.9 0.02
211597_s_at HOPX Homeodomain-only protein 2.8 0.002
209631_s_at GPR37 G protein-coupled receptor 37 (endothelin receptor type B-like) 2.8 0.002
204379_s_at FGFR3 Fibroblast growth factor receptor 3 2.8 0.03
214279_s_at NDRG2 NDRG family member 2 2.7 0.008
Twenty genes most up-regulated in non-responders to chemotherapy
210809_s_at POSTN Periostin, osteoblast specific factor 4.3 0.05
223278_at GJB2 Gap junction protein, beta 2, 26kDa 4.1 0.01
231735_s_at MALAT1 Metastasis associated lung adenocarcinoma transcript 1 3.6 0.003
206785_s_at KLRC1///KLRC2 Killer cell lectin-like receptor subfamily C, member 1///member 2 3.3 0.03
230472_at IRX1 Iroquois homeobox protein 1 3.1 0.03
213350_at RPS11 Ribosomal protein S11 2.8 0.004
228367_at ALPK2 Alpha-kinase 2 2.7 0.01
209644_x_at CDKN2A Cyclin-dependent kinase inhibitor 2A (p16) 2.7 0.04
221872_at RARRES1 Retinoic acid receptor responder (tazarotene induced) 1 2.6 0.04
224321_at TMEFF2 Transmembrane protein with EGF-like and two follistatin-like domains 2 2.5 0.004
225314_at OCIAD2 OCIA domain containing 2 2.5 0.02
206858_s_at HOXC6 Homeobox C6 2.5 0.01
213150_at HOXA10 Homeobox A10 2.4 0.04
235412_at ARHGEF7 Rho guanine nucleotide exchange factor (GEF) 7 2.4 0.03
209687_at CXCL12 Chemokine (C-X-C motif) ligand 12 2.3 0.03
206282_at NEUROD1 Neurogenic differentiation 1 2.2 0.02
227388_at TUSC1 Tumor suppressor candidate 1 2.2 0.0007
1562403_a_at SLC8A3 Solute carrier family 8 (sodium-calcium exchanger), member 3 2.2 0.02
201387_s_at UCHL1 Ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase) 2.2 0.01
231984_at MTAP Methylthioadenosine phosphorylase 2.0 0.0003
List of the 20 genes most up-regulated and with a p-value <0.05 in responders versus non-responders and in non-responders versus responders to first-line
chemotherapy. FC: Fold change, p-value: Limma T-test p-value. Normal brain genes and stem-cell genes are underlined in responders and non-responders,
respectively.
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suggested [41]. Several experimental studies have also
suggested that p16 expression is associated with che-
moresistance in gliomas [42-44]. In order to validate
the association between p16 deletion and chemosensi-
tivity, we assessed the impact of p16 deletion in an
independent series of patients treated either with
radiation therapy alone or with radiation therapy and
adjuvant chemotherapy. In this dataset, we observed a
benefit of adjuvant chemotherapy in both MGMTP
methylated and unmethylated patients when p16 was
deleted, whereas this benefit was only observed in
MGMTP methylated patients when p16 was not
deleted, supporting the association between p16
deletion and chemosensitivity. This also suggests that
p16 deletion might be an alternative mechanism of
chemosensitivity in MGMTP unmethylated patients
and is consistent with our finding that most of the
responders to first-line chemotherapy were MGMTP
unmethylated.
The present study demonstrates that the response of
GBMs to either first-line chemotherapy or radiotherapy
relies on different molecular mechanisms. According to
their transcriptomic and genomic characteristics, some
patients benefit more from chemotherapy and others
more from radiotherapy. These results encourage the
combination of both treatment strategies to increase the
likelihood of treatment response and suggest that prog-
nostic markers could be identified both to predict
Table 8 Characteristics of the patients from the Pitié-Salpêtrière database
Treatment group Age (median) Karnofsky (median) Surgery
(% B/P/C)
MGMTP methylated
P16 not deleted (n = 141)
RT alone N = 47 57 80 8/27/65 55%
RT+CT N = 94 55 80 13/24/63 46%
P16 deleted (n = 81)
RT alone N = 32 57 80 15/25/60 53%
RT+CT N = 49 57 80 10/27/63 53%
Surgery (B/P/C): Percentage of Biopsy/Partial/Complete surgery; MGMTP methylated: percentage of patients with methylated MGMT; RT: radiotherapy; RT+CT:
radiotherapy and adjuvant chemotherapy.
Figure 5 Survival according to treatment, radiotherapy alone or radiotherapy and adjuvant chemotherapy, p16 deletion and MGMTP
methylation in an independent series of 222 GBMs. The y-axis corresponds to the survival probability and the x-axis to survival time
(months). Survival curves on the left correspond to the patients with p16 deletions; survival curves on the right correspond to patients without
p16 deletions. These survival curves show that patients with p16 deletions benefit from adjuvant chemotherapy regardless of their MGMTP
methylation status, whereas patients without p16 deletions benefit from adjuvant chemotherapy only when they have a methylated MGMTP.
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chemo-or radiotherapy efficacy and to develop new
therapeutic strategies.
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